MAP2K1-driven mixed Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease and Erdheim-Chester disease, clonally related to acute myeloid leukemia

被引:5
|
作者
Bonometti, Arturo [1 ]
Ferrario, Giuseppina [2 ]
Parafioriti, Antonina [3 ]
Giardino, Demostene [4 ]
Simonetti, Federico [5 ]
Ginori, Alessandro [6 ]
Passoni, Emanuela [7 ]
Berti, Emilio [7 ,8 ]
机构
[1] Univ Pavia, Dept Mol Med, IRCCS San Matteo Fdn, Unit Anat Pathol, Pavia, Italy
[2] Univ Pavia, Dept Mol Med, IRCCS San Matteo Fdn, Pavia, Italy
[3] ASST PINI CTO Ctr Specialist Ortoped Traumatol Ga, Dept Pathol, Milan, Italy
[4] Casa Cura San Camillo, Surg Pathol Unit, Forte Dei Marmi, Italy
[5] Unico Versilia Hosp, Dept Hematol, Camaiore, Italy
[6] Azienda USL Toscana Nord Ovest, Pathol Unit, Polyspecialist Ctr Monterosso, Carrara, Italy
[7] Osped Maggiore Policlin, Dept Dermatol, Fdn IRCCS Ca Granda, Milan, Italy
[8] Univ Milan, Dept Pathophysiol & Transplantat, IRCCS Fdn, Ca Granda Osped Maggiore Policlin, Milan, Italy
关键词
Langerhans cell histiocytosis; Rosai‐ Dorfman‐ Destombes disease; Erdheim‐ Chester disease; clonal relation; acute myeloid leukemia; MUTATIONS; LYMPHOMA;
D O I
10.1111/cup.13918
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Mixed histiocytoses are a rare and recently recognized subset of histiocytic disorders that may involve the skin, characterized by the synchronous or metachronous development of lesions with Langerhans and/or non-Langerhans cell histiocytosis histopathological features. Around 10% of patients diagnosed with histiocytosis may develop a hematological malignancy, often with dramatic prognostic consequences. We hereby describe the exceptional case of a patient developing a MAP2K1-driven mixed histiocytosis with Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease, and Erdheim-Chester disease features and cutaneous involvement, progressing to a fatal and clonally-related acute myeloid leukemia. We reviewed the literature on similar cases and discussed the histopathological difficulties in their diagnosis and their clinical-pathological features.
引用
收藏
页码:637 / 643
页数:7
相关论文
共 31 条
  • [21] Serial assessments of anterior pituitary hormones in a case of mixed histiocytosis representing Langerhans cell histiocytosis overlapping with Erdheim-Chester disease
    Ito, Kei
    Ito, Jun
    Yamamoto, Yuki
    Nakajima, Rikako
    Fujii, Masanao
    Katakura, Yukino
    Muramatsu, Aiko
    Takayashiki, Norio
    Toyama, Kazuhiro
    Kurokawa, Mineo
    Yagyu, Hiroaki
    ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2021,
  • [22] MEK Inhibition With Trametinib for the treatment of MAP2K1-Mutated Rosai-Dorfman-Destombes Disease Arising from the Nasopharynx in a Paediatric Patient
    Cuerden, Claire
    Alsalem, Mohammad
    Sproson, Eleanor
    Burgess, Andrea
    Jogai, Sanjay
    Portess, Howard
    Deem, Karen
    Ismail-Koch, Hasnaa
    Abla, Oussama
    Bate, Jessica
    PEDIATRIC BLOOD & CANCER, 2025,
  • [23] Langerhans cell histiocytosis and Erdheim-Chester disease overlap syndrome with bone marrow involvement and type 2 diabetes mellitus
    Miao Chen
    Cheng Ding
    Tao Lu
    Na Niu
    Bing Han
    Annals of Hematology, 2018, 97 : 189 - 192
  • [24] Langerhans cell histiocytosis and Erdheim-Chester disease overlap syndrome with bone marrow involvement and type 2 diabetes mellitus
    Chen, Miao
    Ding, Cheng
    Lu, Tao
    Niu, Na
    Han, Bing
    ANNALS OF HEMATOLOGY, 2018, 97 (01) : 189 - 192
  • [25] Erdheim-Chester Disease and Acute Myeloid Leukemia with Mutated NPM1 in a Patient with Clonal Hematopoiesis: A Case Report
    Papageorgiou, Sotirios G.
    Divane, Aspasia
    Roumelioti, Maria
    Kottaridi, Christine
    Bouchla, Anthi
    Georgakopoulos, Alexandros
    Ieremiadou, Fotini
    Daraki, Aggeliki
    Bazani, Efthymia
    Thomopoulos, Thomas P.
    Chatziioannou, Sofia
    Mavrogenis, Andreas
    Panayiotidis, Panayiotis
    Panayiotides, Ioannis G.
    Pappa, Vasiliki
    Foukas, Periklis G.
    ONCOTARGETS AND THERAPY, 2020, 13 : 11689 - 11695
  • [26] Co-occurrence of Erdheim-Chester disease and clonally evolving acute myeloid leukemia with FLT3-ITD and PTPN11 mutations
    Wang, Xue-zhu
    Gao, Xue-min
    Wang, Jun-mei
    Cai, Hao
    Li, Jian
    Cao, Xin-xin
    ANNALS OF HEMATOLOGY, 2024, 103 (08) : 3229 - 3233
  • [27] Erdheim-Chester- und Rosai-Dorfman-ErkrankungKlinisch-radiologisch-pathologische Diagnostik von Non-Langerhans-Zell-Histiozytosen des ErwachsenenaltersErdheim-Chester disease and Rosai-Dorfman diseasePathological, radiological and clinical features of adult non-Langerhans cell histiocytosis
    H. Bösmüller
    D. Nann
    M. Horger
    F. Fend
    Der Pathologe, 2015, 36 (5): : 458 - 466
  • [28] Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim-Chester disease
    Varadi, Zsofia
    Banusz, Rita
    Csomor, Judit
    Kallay, Krisztian
    Varga, Edit
    Kertesz, Gabriella
    Csoka, Monika
    ONCOTARGETS AND THERAPY, 2017, 10 : 521 - 526
  • [29] A phase 2 study of HLX208, a BRAFV600E inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harboring BRAFV600E mutation.
    Cao, Xin-Xin
    Wu, Yu
    Liu, Peng
    Ding, Tianling
    Ye, Hongying
    Cai, Zhen
    Zhang, Yu
    Hu, Chen
    Hou, Xiaoli
    Yang, Guiyu
    Wang, Qingyu
    Zhu, Jun
    Li, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study
    Diamond, Eli L.
    Subbiah, Vivek
    Lockhart, A. Craig
    Blay, Jean-Yves
    Puzanov, Igor
    Chau, Ian
    Raje, Noopur S.
    Wolf, Jurgen
    Erinjeri, Joseph P.
    Torrisi, Jean
    Lacouture, Mario
    Elez, Elena
    Martinez-Valle, Ferran
    Durham, Benjamin
    Arcila, Maria E.
    Ulaner, Gary
    Abdel-Wahab, Omar
    Pitcher, Bethany
    Makrutzki, Martina
    Riehl, Todd
    Baselga, Jose
    Hyman, David M.
    JAMA ONCOLOGY, 2018, 4 (03) : 384 - 388